Skip to main content
See every side of every news story
Published loading...Updated

‘Poop pills’ developed in London show promise for cancer patients in early trial

Early trials show fecal microbiota transplant capsules improve immunotherapy response rates to 75-80% and reduce toxic side effects in kidney cancer patients, researchers say.

  • New studies published in Nature Medicine show LND101 capsules from Lawson Research Institute reduce immunotherapy toxicity and improve responses in kidney, lung, and melanoma cancers, tested at LHSCRI and CRCHUM.
  • Processed stool capsules reshape patients' gut microbiome by using FMT capsules from healthy stool donors to restore patient gut microbiome and eliminate harmful bacteria.
  • Trial data show substantially improved response in lung and melanoma patients, with 80 per cent of patients with non-small-cell lung cancer and 75 per cent of melanoma patients responding after FMT capsules .
  • In the kidney cancer trial, researchers found only one participant had serious side effects and reported a 50 to 60 per cent reduction in symptoms, improving treatment tolerance for advanced kidney cancer patients.
  • As a next step, researchers at Lawson Research Institute and CRCHUM are scaling LND101 production and expanding FMT testing in the pan-Canadian Canbiome2 randomized controlled trial.
Insights by Ground AI

12 Articles

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 72% of the sources are Center
72% Center

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Inside Precision Medicine broke the news in on Wednesday, January 28, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

News
Feed Dots Icon
For You
Search Icon
Search
Blindspot LogoBlindspotLocal